Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature
Academic Article
Publication Date:
2019
Short description:
Second line treatment of recurrent glioblastoma with sunitinib: results of a phase II study and systematic review of literature / Grisanti, S., Ferrari, V.D., Buglione Di Monale E Bastia, M., Agazzi, G.M., Liserre, R., Poliani, P.L., Buttolo, L., Gipponi, S., Pedersini, R., Consoli, F., Panciani, P., Roca, E., Spena, G., Triggiani, L., Berruti, A.. - In: JOURNAL OF NEUROSURGICAL SCIENCES. - ISSN 0390-5616. - 63:4(2019), pp. 458-467. [10.23736/S0390-5616.16.03874-1]
abstract:
Second line treatment of recurrent or progressive glioblastoma multiforme (GBM) is not standardized. Anti-angiogenic strategies with tyrosine-kinase inhibitors have been tested with conflicting results. We tested the association of sunitinib (S) plus irinotecan (CPT-11) in a phase II trial in terms of response rate (RR) and 6-months progression-free survival (6-PFS). We also reviewed the clinical evidence from all the trials with S in this setting published to date and summarized it in a meta-analysis.
Iris type:
1.1.1 Articolo in rivista - Review
List of contributors:
Grisanti, Salvatore; Ferrari, Vittorio Domenico; Buglione Di Monale E Bastia, Michela; Agazzi, Giorgio M; Liserre, Roberto; Poliani, Pietro Luigi; Buttolo, Luciano; Gipponi, Stefano; Pedersini, Rebecca; Consoli, Francesca; Panciani, Pierpaolo; Roca, Elisa; Spena, Giannantonio; Triggiani, Luca; Berruti, Alfredo
Published in: